| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
|
J Clin Oncol
|
2009
|
2.68
|
|
2
|
Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays.
|
Genome Biol
|
2008
|
2.67
|
|
3
|
Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios.
|
BMC Bioinformatics
|
2008
|
2.66
|
|
4
|
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
|
Blood
|
2011
|
2.66
|
|
5
|
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.
|
Nat Genet
|
2010
|
2.45
|
|
6
|
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.
|
Nat Med
|
2005
|
2.36
|
|
7
|
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
|
Blood
|
2010
|
2.33
|
|
8
|
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.
|
Blood
|
2012
|
2.14
|
|
9
|
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.
|
Nat Rev Clin Oncol
|
2012
|
2.05
|
|
10
|
Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.
|
Blood
|
2003
|
1.84
|
|
11
|
Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.
|
Blood
|
2004
|
1.77
|
|
12
|
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.
|
J Clin Oncol
|
2012
|
1.74
|
|
13
|
Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms.
|
Genes Chromosomes Cancer
|
2008
|
1.66
|
|
14
|
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.
|
Blood
|
2005
|
1.63
|
|
15
|
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
|
Lancet Oncol
|
2010
|
1.57
|
|
16
|
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
|
Leuk Res
|
2009
|
1.43
|
|
17
|
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.
|
Blood
|
2003
|
1.33
|
|
18
|
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.
|
Haematologica
|
2011
|
1.25
|
|
19
|
Mechanisms of anti-cancer action and pharmacology of clofarabine.
|
Biochem Pharmacol
|
2009
|
1.21
|
|
20
|
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
|
Blood
|
2005
|
1.18
|
|
21
|
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
|
Br J Haematol
|
2006
|
1.11
|
|
22
|
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.
|
Haematologica
|
2012
|
1.03
|
|
23
|
High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.
|
Haematologica
|
2010
|
1.03
|
|
24
|
Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment.
|
Blood
|
2011
|
1.02
|
|
25
|
Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.
|
Am J Hematol
|
2013
|
0.97
|
|
26
|
TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
|
Leuk Res
|
2010
|
0.96
|
|
27
|
Application of population pharmacokinetics to cladribine.
|
BMC Pharmacol
|
2005
|
0.95
|
|
28
|
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
|
Br J Haematol
|
2012
|
0.95
|
|
29
|
Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk.
|
Br J Haematol
|
2010
|
0.93
|
|
30
|
Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies.
|
Hum Mol Genet
|
2004
|
0.93
|
|
31
|
LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.
|
Haematologica
|
2011
|
0.93
|
|
32
|
Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.
|
Am J Hematol
|
2015
|
0.91
|
|
33
|
Globalization, climate change, and human health.
|
N Engl J Med
|
2013
|
0.91
|
|
34
|
Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia.
|
Am J Hematol
|
2012
|
0.91
|
|
35
|
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
|
Cancer
|
2008
|
0.89
|
|
36
|
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.
|
Blood
|
2013
|
0.89
|
|
37
|
Population-based analyses in adult acute lymphoblastic leukemia.
|
Blood
|
2010
|
0.88
|
|
38
|
Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia.
|
Cancer Lett
|
2004
|
0.88
|
|
39
|
High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
|
Biol Blood Marrow Transplant
|
2009
|
0.87
|
|
40
|
Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.
|
Haematologica
|
2010
|
0.85
|
|
41
|
NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients.
|
BMC Cancer
|
2013
|
0.84
|
|
42
|
Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles.
|
Epigenetics
|
2012
|
0.83
|
|
43
|
RT-PCR analysis of acute myeloid leukemia with t(8;16)(p11;p13): identification of a novel MOZ/CBP transcript and absence of CBP/MOZ expression.
|
Genes Chromosomes Cancer
|
2002
|
0.83
|
|
44
|
The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia.
|
Biochem Pharmacol
|
2006
|
0.82
|
|
45
|
Rapid and effective CD3 T-cell depletion with a magnetic cell sorting program to produce peripheral blood progenitor cell products for haploidentical transplantation in children and adults.
|
Transfusion
|
2007
|
0.82
|
|
46
|
Pharmacological basis for cladribine resistance.
|
Leuk Lymphoma
|
2003
|
0.81
|
|
47
|
IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.81
|
|
48
|
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.
|
Br J Haematol
|
2004
|
0.81
|
|
49
|
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
|
Am J Hematol
|
2014
|
0.81
|
|
50
|
A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
|
Haematologica
|
2004
|
0.78
|
|
51
|
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
|
Leuk Res
|
2003
|
0.78
|
|
52
|
Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
|
Leuk Lymphoma
|
2012
|
0.78
|
|
53
|
Leukemia.
|
Prog Tumor Res
|
2016
|
0.77
|
|
54
|
Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden.
|
Leuk Lymphoma
|
2010
|
0.76
|
|
55
|
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.
|
Br J Haematol
|
2002
|
0.75
|
|
56
|
Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study.
|
Leuk Lymphoma
|
2011
|
0.75
|
|
57
|
[Collection of fetal blood should be publicly financed].
|
Lakartidningen
|
2005
|
0.75
|
|
58
|
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
59
|
rs2072135, a low-penetrance variant for chronic lymphocytic leukaemia?
|
Br J Haematol
|
2013
|
0.75
|
|
60
|
Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.
|
Eur J Haematol
|
2014
|
0.75
|
|
61
|
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.
|
Acta Haematol
|
2015
|
0.75
|
|
62
|
High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse.
|
Med Oncol
|
2013
|
0.75
|
|
63
|
Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: a retrospective study.
|
Am J Hematol
|
2011
|
0.75
|